Readoutin 14d
BeOne Medicines — Zanubrutinib
Phase 3 primary completion: A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib.
- Date
- Dec 2026
- Type
- Readout
- Indication
- B-cell Malignancies